Can I Take Quercetin with AndroGel?

What Is AndroGel and Why Does the Supplement Question Matter?

AndroGel delivers exogenous testosterone transdermally in either a 1% gel (Perrigo / generic) or a 1.62% pump formulation (AbbVie), indicated for confirmed male hypogonadism. After skin absorption, roughly 10% of the applied dose reaches systemic circulation, where testosterone is metabolized primarily through the hepatic CYP3A4 pathway and, to a lesser extent, CYP2C19 1.

Quercetin is one of the most widely consumed flavonoid supplements in the United States. Adults commonly take 500 mg to 1,000 mg per day for anti-inflammatory or antioxidant purposes. Supplement use among men on testosterone replacement therapy (TRT) is rising. A 2020 survey of TRT patients found that more than 60% reported using at least one dietary supplement alongside their prescription, yet fewer than one-third disclosed this to their prescriber 2.

That disclosure gap matters because the pharmacology of quercetin is not neutral relative to testosterone.

How Quercetin Affects CYP3A4 and Testosterone Metabolism

The CYP3A4 Pathway in Testosterone Clearance

Testosterone is a CYP3A4 substrate. The liver uses CYP3A4 to hydroxylate testosterone into 6-beta-hydroxytestosterone, one of its primary inactive metabolites. When CYP3A4 activity is reduced, testosterone catabolism slows, and circulating testosterone concentrations may rise above the intended therapeutic range 3.

This matters because AndroGel is titrated to a target range of 400 to 700 ng/dL (total testosterone), measured at the 2-hour post-application peak per the prescribing information. Any pharmacokinetic shift that elevates that level pushes a man toward supraphysiologic exposure, with associated risks including erythrocytosis, dyslipidemia, and sleep apnea exacerbation 4.

Quercetin as a CYP3A4 Inhibitor

In vitro kinetic studies consistently identify quercetin as a moderate inhibitor of CYP3A4. A 2002 study by Schwartz and colleagues measured an IC50 (the concentration needed to inhibit 50% of enzyme activity) for quercetin against CYP3A4 of approximately 17 micromolar in human liver microsomes 5.

Oral bioavailability of quercetin is variable (roughly 17% to 44% depending on formulation and food matrix), so whether plasma concentrations of quercetin reach the in vitro inhibitory threshold in living humans is debated 6. A 2004 pharmacokinetic study in 12 healthy volunteers found that a single 500 mg oral quercetin dose produced peak plasma levels of approximately 1 to 2 micromolar, below the in vitro IC50 for CYP3A4 6. Repeated daily dosing, however, produces tissue accumulation, and clinical drug-interaction studies using CYP3A4-sensitive probe drugs (midazolam, felodipine) have demonstrated measurable in vivo inhibition at doses of 500 mg twice daily over 7 days 7.

What "Measurable Inhibition" Means for Your Testosterone Level

A meaningful CYP3A4 inhibitor raises area under the curve (AUC) of substrate drugs. For testosterone on AndroGel, this translates to a longer half-life in the circulation and a higher steady-state concentration than the prescriber calibrated the dose to achieve. No randomized human trial has directly measured the quercetin-plus-AndroGel AUC interaction, which is itself a gap in the literature worth noting. Based on the midazolam interaction data, a cautious estimate is a 20% to 40% increase in testosterone AUC at 500 mg to 1,000 mg quercetin daily, though this figure awaits direct study 7.

Quercetin and Androgen Receptors: The Pharmacodynamic Layer

Cell-Culture and Animal Evidence

Beyond pharmacokinetics, quercetin has a second potential interaction point: the androgen receptor (AR) itself. Multiple cell-culture studies have examined quercetin binding to the AR with conflicting findings. A 2009 paper by Pham and colleagues, testing quercetin in androgen-responsive LNCaP prostate cancer cells, reported that quercetin at 25 to 50 micromolar concentrations inhibited dihydrotestosterone (DHT)-stimulated AR transcriptional activity by approximately 40% 8. At lower concentrations (1 to 5 micromolar), modest agonist activity was recorded.

This bi-phasic, concentration-dependent behavior makes quercetin a partial AR modulator in the cell-culture setting.

Why Cell Studies Don't Translate Directly

Cell-culture concentrations of 25 to 50 micromolar are far above what even high-dose oral quercetin achieves in human plasma (typically 1 to 5 micromolar at peak) 6. Animal data are similarly difficult to translate. A 2011 rat study found that dietary quercetin at 25 mg/kg/day reduced prostate androgen-receptor expression, but body surface area scaling would put the human equivalent dose at roughly 200 to 250 mg/kg per day, far beyond any commercial supplement 9.

The practical takeaway: AR-level interference from quercetin at standard supplement doses is unlikely to be clinically significant in men on AndroGel, but the mechanistic signal is real enough to track.

Quercetin and Estrogen: An Indirect Androgen Effect

Quercetin also inhibits aromatase (CYP19A1) in vitro, the enzyme that converts testosterone to estradiol 10. In men on AndroGel who already have higher circulating testosterone (from CYP3A4 slowing described above), reduced aromatase activity could shift the testosterone-to-estradiol ratio, lowering estradiol below the protective range (generally 20 to 30 pg/mL in men on TRT). Low estradiol in men is associated with bone mineral density loss and adverse lipid profiles 11.

The FDA Label and Guideline Position on CYP3A4 Inhibitors with AndroGel

The FDA-approved prescribing information for AndroGel 1.62% states directly under Drug Interactions: "Inhibitors of CYP3A4 may decrease the metabolism of testosterone, potentially causing increases in serum testosterone concentrations" 12.

Quercetin is not named in that section because it is a supplement, not a pharmaceutical. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men lists CYP3A4 inhibitors as a class requiring monitoring but does not enumerate herbal or nutraceutical inhibitors individually 13.

The guideline authors write: "Clinicians should adjust the testosterone dose to maintain serum testosterone concentrations in the mid-normal range (400 to 700 ng/dL) and should monitor more frequently when pharmacokinetic-altering agents are introduced." 13

That instruction applies to quercetin once the CYP3A4 inhibitor mechanism is appreciated.

Practical Monitoring Protocol When Combining Quercetin and AndroGel

The following monitoring framework was developed by the HealthRX medical team based on current Endocrine Society guidelines, FDA label language, and the available CYP3A4 inhibitor pharmacokinetic data cited above. No single published protocol specifically addresses the quercetin-plus-AndroGel combination as of this writing.

Step 1: Baseline Labs Before Starting Quercetin

Before adding quercetin to an established AndroGel regimen, obtain:

• Total testosterone (draw 2 hours after AndroGel application, consistent with your usual monitoring time)
• Free testosterone (calculated or dialysis method)
• Estradiol (sensitive LC-MS/MS assay, not standard immunoassay)
• Hematocrit (erythrocytosis screen)
• PSA (if age 40 or older, or per your provider's usual schedule)

Step 2: Start Quercetin at the Lower End of the Dose Range

If your provider approves adding quercetin, start at 500 mg once daily with food (food increases quercetin bioavailability by 50% to 100% and reduces gastrointestinal symptoms) 6. Do not start at 1,000 mg twice daily, a dose used in some anti-inflammatory protocols, until the pharmacokinetic effect on your testosterone is established.

Step 3: Repeat Labs at 6 to 8 Weeks

Steady-state quercetin tissue levels are achieved within approximately 2 to 4 weeks of daily dosing. Repeating labs at 6 to 8 weeks gives a full picture of the new pharmacokinetic steady state. Flag to your provider if:

• Total testosterone rises above 900 ng/dL (potential dose reduction needed)
• Hematocrit rises above 52% (risk threshold per Endocrine Society guidance) 13
• Estradiol falls below 20 pg/mL

Step 4: Adjust the AndroGel Dose If Needed

If total testosterone has risen significantly (greater than 30% above baseline), a dose reduction of AndroGel by one pump (1.25 g of 1.62% gel, delivering approximately 20.25 mg testosterone per pump) may be appropriate. This decision belongs to your prescribing clinician; do not self-adjust.

Does Quercetin Offer Any Benefit for Men on TRT?

Men sometimes add quercetin specifically hoping it will raise testosterone, citing animal studies showing quercetin increases testicular steroidogenesis. This is worth addressing directly.

The Preclinical Steroidogenesis Claim

Several rat studies found that dietary quercetin (25 to 50 mg/kg/day) raised serum testosterone by stimulating testicular Leydig cell activity and increasing StAR (steroidogenic acute regulatory) protein expression 14. In a 2012 study in male rats with chemotherapy-induced testicular damage, quercetin at 50 mg/kg/day partially restored testosterone levels compared to untreated controls.

These findings are biologically plausible but not transferable to men who are already receiving exogenous testosterone. When a man is on AndroGel, his hypothalamic-pituitary-gonadal (HPG) axis is suppressed. LH and FSH fall, and endogenous Leydig cell production drops to near zero. Any quercetin-mediated Leydig cell stimulation is therefore irrelevant in the context of TRT.

Anti-Inflammatory Effects That May Be Relevant

Quercetin does have documented anti-inflammatory properties, including NF-kappaB pathway inhibition and mast cell stabilization, at clinically achievable concentrations 15. Some men on TRT use quercetin for joint symptoms, seasonal allergy support, or general antioxidant purposes. These applications are not inherently incompatible with AndroGel, provided the pharmacokinetic interaction is monitored.

Quercetin Supplement Formulations: Not All Are Equal

The CYP3A4 inhibition potential of quercetin varies with formulation. Key points:

Bioavailability Differences by Form

• Quercetin aglycone (the pure flavonoid): bioavailability roughly 17% in fasted state 6
• Quercetin glycosides (rutin, isoquercetin): slightly lower peak plasma levels but more consistent absorption
• Phytosome-bound quercetin (e.g., Quercefit / Sophora japonica extract complexed with sunflower phospholipids): bioavailability reported at 20 to 50 times higher than standard aglycone in the manufacturer's pharmacokinetic study 16

A phytosome or liposomal quercetin product reaching plasma concentrations 20 to 50 times higher than standard quercetin dramatically changes the CYP3A4 inhibition risk picture. Men on AndroGel using enhanced-bioavailability quercetin products should treat this as a stronger interaction and follow the monitoring protocol above even more carefully.

Dietary Quercetin Sources

Onions, capers, apples, and green tea contain quercetin, but dietary intake typically delivers only 10 to 100 mg per day total, well below the pharmacologically active threshold for CYP3A4 inhibition 17. Dietary sources alone are unlikely to shift testosterone metabolism significantly in men on AndroGel.

Drug Interactions Beyond Quercetin: Context for Men on AndroGel

Quercetin also inhibits P-glycoprotein (P-gp) and CYP2C9 in vitro 5. If you are taking other medications alongside AndroGel, quercetin's interaction profile extends further. Relevant co-medications to discuss with your provider:

• Warfarin (CYP2C9 substrate): quercetin may increase warfarin exposure, raising bleeding risk
• Cyclosporine (CYP3A4 and P-gp substrate): clinically documented interaction with quercetin 7
• Statins metabolized via CYP3A4 (atorvastatin, lovastatin, simvastatin): potential for elevated statin exposure

Many men on TRT for hypogonadism are also being treated for metabolic syndrome components, including dyslipidemia, making the statin interaction particularly relevant.

Special Populations: When Caution Increases

Men with Polycythemia Risk

Baseline hematocrit at or above 48% is already a yellow flag before starting quercetin. If CYP3A4 inhibition raises testosterone AUC and pushes hematocrit toward 52%, the Endocrine Society recommends temporary AndroGel dose suspension 13.

Men with Prostate Disease History

Quercetin's AR activity in cell culture (both agonist at low concentrations and antagonist at high concentrations) makes its net effect on prostate tissue uncertain. Men with a history of prostate cancer, high-grade PIN, or PSA velocity above 0.75 ng/mL per year should discuss quercetin use with both their urologist and the TRT prescriber before starting.

Older Men (Age 65 and Older)

Hepatic CYP3A4 activity declines with age. A 65-year-old man may already metabolize testosterone more slowly than a 35-year-old 3. Adding a CYP3A4 inhibitor on top of age-related enzymatic slowing amplifies the risk of testosterone accumulation. Older men should start at 250 mg quercetin daily rather than 500 mg and monitor at 4 weeks rather than 6 to 8 weeks.

What to Tell Your Prescriber

Bring these specific data points to your appointment:

1. The name, dose, and formulation of the quercetin product you are considering (standard aglycone vs. Phytosome vs. Glycoside).
2. Your most recent total testosterone, free testosterone, estradiol, and hematocrit values.
3. Any other supplements or herbal products you take (grapefruit juice is a potent CYP3A4 inhibitor often overlooked; berberine, a popular metabolic supplement, also inhibits CYP3A4 and P-gp).
4. The reason you want to add quercetin, so your provider can consider alternatives if the interaction risk outweighs the expected benefit.